Katharine J. Ross focuses her practice on commercial litigation. She has experience representing clients in a broad range of matters, including corporate restructurings, class actions, and insider trading.
Prior to joining the firm, Ms. Ross was an associate at Cleary Gottlieb Steen & Hamilton LLP, where she represented clients in a variety of civil litigation and corporate restructuring matters.
While in law school, Ms. Ross served as co-president of the American Constitution Society and as articles editor for the Legal Forum. She also participated in the Exoneration Project Clinic.
Experience
Representing Samsung Bioepis against a breach-of-contract lawsuit brought by Johnson & Johnson and Janssen Biotech concerning Samsung’s manufacture of the biosimilar Ustekinumab-ttwe. Defeated two attempts to obtain preliminary injunctions against Samsung Bioepis and won appeal defending favorable district court order. (See “J&J Loses Appeal to Block Samsung’s Stelara Biosimilar Drug Copy,” Bloomberg; “J&J sues Samsung Bioepis over Stelara biosimilar,” Reuters).
Represented a global technology and services provider in class action lawsuits and Sixth Circuit appeals related to diesel-engine emissions technology.
Represented a telecommunications company as a third-party witness in an insider trading investigation by the Securities and Exchange Commission.
Represented law professors as amici curiae in Sixth Circuit appeal involving Title IX claims by former student-athletes against the Ohio State University.
Represented a prominent financial institution and affiliates in a bankruptcy adversary proceeding arising out of the Bernie Madoff fraud.
Recognitions
- Most Promising Newcomer, The Recorder (finalist) (2025)
Insights
-
Co-author, “SPAC Bankruptcies,” Turnarounds & Workouts (June 2023)